BARDA, Tangen Biosciences partnership pursues SARS-CoV-2 diagnostic

The Biomedical Advanced Research and Development Authority (BARDA) and Tangen Biosciences, Inc. are teaming up to develop a rapid diagnostic test for SARS-CoV-2, capable of producing results within an hour.

The test will be paired with the Tangen GeneSpark, a molecular diagnostic system, and operate through samples taken from the back of the nose or throat. Results would be delivered through a cloud-based mobile platform capable of granting de-identified test results to public health agencies. In this way, the pair hope that the system could help public health departments better monitor the spread of COVID-19, which SARS-CoV-2 causes, and decrease the number of infections spreading through communities.

Under the agreement, the Connecticut-based Tangen will develop the test with the goal of getting it CLIA waived for use in doctors’ offices throughout the country. It is meant for use on those who display COVID-19 symptoms, to assess patients early and quickly. If successfully developed, it will seek emergency use authorization (EUA) from the U.S. Food and Drug Administration.